Docality.com Logo
 
Dr. Thomas  Jones  Md image

Dr. Thomas Jones Md

2491 Mission Hill Drive
Perrysburg OH 43551
419 749-9813
Medical School: Wayne State University School Of Medicine - 1997
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: No
License #: 35082457
NPI: 1386665719
Taxonomy Codes:
2085R0202X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Thomas Jones is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:72141 Description:Mri neck spine w/o dye Average Price:$270.00 Average Price Allowed
By Medicare:
$77.61
HCPCS Code:72148 Description:Mri lumbar spine w/o dye Average Price:$250.00 Average Price Allowed
By Medicare:
$71.71
HCPCS Code:72148 Description:Mri lumbar spine w/o dye Average Price:$250.00 Average Price Allowed
By Medicare:
$72.27
HCPCS Code:72195 Description:Mri pelvis w/o dye Average Price:$240.00 Average Price Allowed
By Medicare:
$70.16
HCPCS Code:73718 Description:Mri lower extremity w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$62.32
HCPCS Code:73218 Description:Mri upper extremity w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$63.02
HCPCS Code:73721 Description:Mri jnt of lwr extre w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$65.55
HCPCS Code:73221 Description:Mri joint upr extrem w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$66.01
HCPCS Code:73721 Description:Mri jnt of lwr extre w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$66.10
HCPCS Code:73221 Description:Mri joint upr extrem w/o dye Average Price:$230.00 Average Price Allowed
By Medicare:
$66.28

HCPCS Code Definitions

73221
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)
73218
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s)
72195
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)
73221
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)
73718
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)
73721
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material
73721
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material
72148
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material
72141
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material
72148
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1124027776
Hematology/Oncology
5,949
1205891579
Diagnostic Radiology
5,157
1992704324
Cardiovascular Disease (Cardiology)
3,621
1639159528
Internal Medicine
3,611
1558300285
Orthopedic Surgery
3,443
1093779548
Diagnostic Radiology
3,440
1801989959
Family Practice
3,079
1013985605
Internal Medicine
2,627
1467437160
General Surgery
2,417
1629032479
Diagnostic Radiology
2,232
*These referrals represent the top 10 that Dr. Jones has made to other doctors

Publications

Greed and Fear in Network Reciprocity: Implications for Cooperation among Organizations. - PloS one
Extensive interdisciplinary literatures have built on the seminal spatial dilemmas model, which depicts the evolution of cooperation on regular lattices, with strategies propagating locally by relative fitness. In this model agents may cooperate with neighbors, paying an individual cost to enhance their collective welfare, or they may exploit cooperative neighbors and diminish collective welfare. Recent research has extended the model in numerous ways, incorporating behavioral noise, implementing other network topologies or adaptive networks, and employing alternative dynamics of replication. Although the underlying dilemma arises from two distinct dimensions-the gains for exploiting cooperative partners (Greed) and the cost of cooperating with exploitative partners (Fear)-most work following from the spatial dilemmas model has argued or assumed that the dilemma can be represented with a single parameter: This research has typically examined Greed or Fear in isolation, or a composite such as the K-index of Cooperation or the ratio of the benefit to cost of cooperation. We challenge this claim on theoretical grounds-showing that embedding interaction in networks generally leads Greed and Fear to have divergent, interactive, and highly nonlinear effects on cooperation at the macro level, even when individuals respond identically to Greed and Fear. Using computational experiments, we characterize both dynamic local behavior and long run outcomes across regions of this space. We also simulate interventions to investigate changes of Greed and Fear over time, showing how model behavior changes asymmetrically as boundaries in payoff space are crossed, leading some interventions to have irreversible effects on cooperation. We then replicate our experiments on inter-organizational network data derived from links through shared directors among 2,400 large US corporations, thus demonstrating our findings for Greed and Fear on a naturally-occurring network. In closing, we discuss implications of our main findings regarding Greed and Fear for the problem of cooperation on inter-organizational networks.
Immunogenicity, Tolerability, and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. - The Pediatric infectious disease journal
This study in healthy adolescents (11 to <18 years) evaluated coadministration of quadrivalent human papillomavirus vaccine, HPV4, with bivalent rLP2086, a meningococcal serogroup B (MnB) vaccine.Subjects received bivalent rLP2086+HPV4, bivalent rLP2086+saline, or saline+HPV4 at 0, 2, and 6 months. Immune responses to HPV4 antigens were assessed one month after doses 2 and 3. Serum bactericidal assays using human complement (hSBAs) with 4 MnB test strains expressing vaccine-heterologous human complement factor H binding protein (fHBP) variants determined immune responses to bivalent rLP2086. Coprimary objectives were to demonstrate noninferior immune responses with concomitant administration compared to either vaccine alone. Additional endpoints included the proportions of subjects achieving prespecified protective hSBA titers to all 4 MnB test strains (composite response) and ≥4-fold increases in hSBA titer from baseline for each test strain after dose 3; these endpoints served as the basis of licensure of bivalent rLP2086 in the United States.The noninferiority criteria were met for all MnB test strains and HPV antigens except HPV-18; ≥99% of subjects seroconverted for all 4 HPV antigens. Bivalent rLP2086 elicited a composite response in >80% of subjects and increased hSBA titers ≥4-fold in ≥77% of subjects for each test strain after dose 3. A substantial bactericidal response was also observed in a large proportion of subjects after dose 2. Local reactions and systemic events did not increase with concomitant administration.Concomitant administration of bivalent rLP2086 and HPV4 elicits robust immune responses to both vaccines without increasing reactogenicity compared to bivalent rLP2086 alone. Concurrent administration may increase compliance with both vaccine schedules.
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. - Journal of the Pediatric Infectious Diseases Society
Concomitant administration of bivalent rLP2086 (Trumenba [Pfizer, Inc] and diphtheria, tetanus, and acellular pertussis and inactivated poliovirus vaccine (DTaP/IPV) was immunologically noninferior to DTaP/IPV and saline and was safe and well tolerated. Bivalent rLP2086 elicited robust and broad bactericidal antibody responses to diverse Neisseria meningitidis serogroup B strains expressing antigens heterologous to vaccine antigens after 2 and 3 vaccinations.Bivalent rLP2086, a Neisseria meningitidis serogroup B (MnB) vaccine (Trumenba [Pfizer, Inc]) recently approved in the United States to prevent invasive MnB disease in individuals aged 10-25 years, contains recombinant subfamily A and B factor H binding proteins (fHBPs). This study evaluated the coadministration of Repevax (diphtheria, tetanus, and acellular pertussis and inactivated poliovirus vaccine [DTaP/IPV]) (Sanofi Pasteur MSD, Ltd) and bivalent rLP2086.Healthy adolescents aged ≥11 to <19 years received bivalent rLP2086 + DTaP/IPV or saline + DTaP/IPV at month 0 and bivalent rLP2086 or saline at months 2 and 6. The primary end point was the proportion of participants in whom prespecified levels of antibodies to DTaP/IPV were achieved 1 month after DTaP/IPV administration. Immune responses to bivalent rLP2086 were measured with serum bactericidal assays using human complement (hSBAs) against 4 MnB test strains expressing fHBP subfamily A or B proteins different from the vaccine antigens.Participants were randomly assigned to receive bivalent rLP2086 + DTaP/IPV (n = 373) or saline + DTaP/IPV (n = 376). Immune responses to DTaP/IPV in participants who received bivalent rLP2086 + DTaP/IPV were noninferior to those in participants who received saline + DTaP/IPV.The proportions of bivalent rLP2086 + DTaP/IPV recipients with prespecified seroprotective hSBA titers to the 4 MnB test strains were 55.5%-97.3% after vaccination 2 and 81.5%-100% after vaccination 3. The administration of bivalent rLP2086 was well tolerated and resulted in few serious adverse events.Immune responses to DTaP/IPV administered with bivalent rLP2086 to adolescents were noninferior to DTaP/IPV administered alone. Bivalent rLP2086 was well tolerated and elicited substantial and broad bactericidal responses to diverse MnB strains in a high proportion of recipients after 2 vaccinations, and these responses were further enhanced after 3 vaccinations.ClinicalTrials.gov identifier NCT01323270.© The Author 2016. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society.
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. - Vaccine
The bivalent rLP2086 vaccine is approved in the United States to prevent meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10-25 years. The immunogenicity and safety of bivalent rLP2086 were evaluated in microbiologists 24-62 years old who handle MnB.Seven subjects vaccinated at 0, 2, and 6 months had functional antibodies measured before vaccination and 1 month after each dose by serum bactericidal assays using human complement (hSBAs) and 4 vaccine-heterologous MnB test strains.Six subjects qualified for analysis. All demonstrated hSBA titers ≥the lower limit of quantitation (LLOQ) against 3 of 4 strains; 3 subjects achieved titers ≥LLOQ for the fourth. Safety-related events following vaccination were generally mild to moderate in severity.Three doses of bivalent rLP2086 were generally well tolerated in laboratory personnel and elicited protective functional immune responses reflective of broad coverage against MnB disease.Copyright © 2015 Elsevier Ltd. All rights reserved.
JigCell Run Manager (JC-RM): a tool for managing large sets of biochemical model parametrizations. - BMC systems biology
Most biomolecular reaction modeling tools allow users to build models with a single list of parameter values. However, a common scenario involves different parameterizations of the model to account for the results of related experiments, for example, to define the phenotypes for a variety of mutations (gene knockout, over expression, etc.) of a specific biochemical network. This scenario is not well supported by existing model editors, forcing the user to manually generate, store, and maintain many variations of the same model.We developed an extension to our modeling editor called the JigCell Run Manager (JC-RM). JC-RM allows the modeler to define a hierarchy of parameter values, simulations, and plot settings, and to save them together with the initial model. JC-RM supports generation of simulation plots, as well as export to COPASI and SBML (L3V1) for further analysis.Developing a model with its initial list of parameter values is just the first step in modeling a biological system. Models are often parameterized in many different ways to account for mutations of the organism and/or for sets of related experiments performed on the organism. JC-RM offers two critical features: it supports the everyday management of a large model, complete with its parameterizations, and it facilitates sharing this information before and after publication. JC-RM allows the modeler to define a hierarchy of parameter values, simulation, and plot settings, and to maintain a relationship between this hierarchy and the initial model. JC-RM is implemented in Java and uses the COPASI API. JC-RM runs on all major operating systems, with minimal system requirements. Installers, source code, user manual, and examples can be found at the COPASI website ( http://www.copasi.org/Projects ).
Signalling Responses Following Varying Sequencing of Strength and Endurance Training in a Fed State. - International journal of sports physiology and performance
The objective of this study was to compare anabolic signalling responses to differing sequences of concurrent strength and endurance training in a fed state.Eighteen resistance-trained males were randomly assigned to the following experimental conditions; i) strength training (ST), ii) strength followed by endurance training (ST-END) or iii) endurance followed by strength training (END-ST). Muscle tissue samples were taken from the vastus lateralis before each exercise protocol, upon cessation of exercise, and 1 h-post cessation of strength training. Tissue was analysed for total and phosphorylated (p-) signalling proteins linked to the mTOR and AMPK networks.Strength training performance was similar between ST, ST-END and END-ST. p-S6k1 was elevated from baseline 1 h post training in ST and ST-END (both p < 0.05). p-4E-BP1 was significantly lower than baseline post ST (p = 0.01), while 1 h post exercise in the ST-END condition p-4E-BP1 was significantly greater than post exercise (p = 0.04). p-ACC was elevated from baseline both post and 1 h post exercise (both p < 0.05) in the END-ST condition. AMPK, mTOR, p38, PKB, eEF2 responded similarly to the ST, ST-END and END-ST. Signalling responses to ST, ST-END and END were largely similar. As such it cannot be ascertained which sequence of concurrent strength and endurance training is most favourable in promoting anabolic signalling.These data indicate that in the case of the present study an acute bout of concurrent training of differing sequences elicited similar responses of the AMPK and mTOR networks.
The Dfam database of repetitive DNA families. - Nucleic acids research
Repetitive DNA, especially that due to transposable elements (TEs), makes up a large fraction of many genomes. Dfam is an open access database of families of repetitive DNA elements, in which each family is represented by a multiple sequence alignment and a profile hidden Markov model (HMM). The initial release of Dfam, featured in the 2013 NAR Database Issue, contained 1143 families of repetitive elements found in humans, and was used to produce more than 100 Mb of additional annotation of TE-derived regions in the human genome, with improved speed. Here, we describe recent advances, most notably expansion to 4150 total families including a comprehensive set of known repeat families from four new organisms (mouse, zebrafish, fly and nematode). We describe improvements to coverage, and to our methods for identifying and reducing false annotation. We also describe updates to the website interface. The Dfam website has moved to http://dfam.org. Seed alignments, profile HMMs, hit lists and other underlying data are available for download.© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
Evaluation and management of congenital peripheral arteriovenous malformations. - Journal of vascular surgery
The International Society for Study of Vascular Anomalies (ISSVA) broadly categorizes vascular anomalies into vascular tumors and vascular malformations. Vascular malformations are further divided based on their flow properties into slow-flow venous and lymphatic malformations, high-flow arteriovenous malformations (AVMs), and congenital mixed syndromes, which can include combinations thereof. Whether occurring in isolation or as part of a broader syndrome, congenital high-flow AVMs are arguably the most complicated, challenging, and gratifying of all vascular malformations to diagnose and manage. Various configurations exist depending on location and coexisting clinical features. Transcatheter embolization has evolved into the mainstay of treatment for most congenital peripheral AVMs with surgical excision playing a growingly limited role as an adjunctive modality. Successful treatment requires technical precision, creativity, patience, and persistence given the ever-evolving angioarchitecture and hemodynamic profile of these lesions. Despite these challenges, certain fundamental principles have been established as our understanding of the pathogenesis, natural history, hemodynamics, and treatment outcomes has expanded and evolved over the last few decades. These principles are crucial to adhere to in the overall management of these lesions and are highlighted and expanded upon herein.Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
The effect of age on the relationship between cardiac and vascular function. - Mechanisms of ageing and development
Age-related changes in cardiac and vascular function are associated with increased risk of cardiovascular mortality and morbidity. The aim of the present study was to define the effect of age on the relationship between cardiac and vascular function. Haemodynamic and gas exchange measurements were performed at rest and peak exercise in healthy individuals. Augmentation index was measured at rest. Cardiac power output, a measure of overall cardiac function, was calculated as the product of cardiac output and mean arterial blood pressure. Augmentation index was significantly higher in older than younger participants (27.7±10.1 vs. 2.5±10.1%, P<0.01). Older people demonstrated significantly higher stroke volume and mean arterial blood pressure (P<0.05), but lower heart rate (145±13 vs. 172±10 beats/min, P<0.01) and peak oxygen consumption (22.5±5.2 vs. 41.2±8.4ml/kg/min, P<0.01). There was a significant negative relationship between augmentation index and peak exercise cardiac power output (r=-0.73, P=0.02) and cardiac output (r=-0.69, P=0.03) in older participants. Older people maintain maximal cardiac function due to increased stroke volume. Vascular function is a strong predictor of overall cardiac function in older but in not younger people.Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
Shunt Lesions. - Cardiology clinics
Intracardiac shunts are among the most common cardiac lesions seen in adult patients with congenital heart disease. Shunt lesions comprise much of the de novo congenital heart disease diagnosed in adults and engender a wide range of pathophysiologic consequences with a variety of treatment options. This article discusses the pathophysiology, clinical presentation, indications for intervention, late management issues, and pregnancy in adults with atrial septal defects, ventricular septal defects, and patent ductus arteriosus.Copyright © 2015 Elsevier Inc. All rights reserved.

Map & Directions

2491 Mission Hill Drive Perrysburg, OH 43551
View Directions In Google Maps

Nearby Doctors

26597 N. Dixie Hwy Ste. 159
Perrysburg, OH 43551
419 749-9744
1011 Sandusky St Suite-C
Perrysburg, OH 43551
419 749-9101
775 W South Boundary St
Perrysburg, OH 43551
419 740-0405
3255 Levis Commons Blvd
Perrysburg, OH 43551
419 740-0393
139 W Indiana Ave
Perrysburg, OH 43551
419 729-9191
702 Commerce Dr Ste 160
Perrysburg, OH 43551
419 727-7600
28370 Kensington Ln Suite A
Perrysburg, OH 43551
419 743-3125
702 Commerce Dr
Perrysburg, OH 43551
419 724-4673
11201 Sandusky St 101
Perrysburg, OH 43551
419 742-2263